Chronic exposure to a number of chlorinated pesticides, including dieldrin, results in an increased incidence and/ or multiplicity of hepatocellular neoplasia in mice, with no such effect in similarly treated rats. One possible explanation of this observed selective carcinogenicity is speciesspecific hepatic tumor promotion. In the present study we examined the dose-response effect of dieldrin (at several doses) on focal lesion growth (tumor promotion), hepatocyte apoptosis and DNA synthesis in rat and mouse liver. Preneoplastic focal hepatic lesions were produced by diethylnitrosamine (DEN). After the lesions developed, mice and rats were placed into one of the following dose groups: control (NIH-07 diet) or 0.1, 1.0 or 10.0 mg dieldrin/kg diet. Increased focal lesion volume, number of foci per liver and focal DNA synthetic labeling index were observed in 10 mg dieldrin/kg diet-treated mice, but not in similarly treated rats. Dieldrin at dietary concentrations of 0.1 and 1.0 mg/kg diet produced an increase in the number of preneoplastic lesions (0.1 mg/kg diet at 7 days only) and focal volume (0.1 mg/kg diet at 7 and 30 days, 1.0 mg/kg diet at 30 days), but these concentrations did not increase focal DNA labeling index. At dietary concentrations of 0.1, 1.0 and 10 mg dieldrin/kg diet no significant change in lesion percent volume, number of preneoplastic lesions per liver or preneoplastic lesion DNA labeling index was seen in treated rats compared with control rats. Apoptosis, a form of programed cell death, was not decreased in foci by any concentration of dieldrin in either rats or mice. Thus our results suggest that dieldrin may function as a mouse-specific tumor promoter through increased lesion DNA synthesis.
Introduction
Many chlorinated pesticides, including the cyclodiene dieldrin, are mouse-specific non-genotoxic hepatocarcinogens (1) (2) (3) (4) (5) . Dieldrin has been shown to be selectively hepatocarcinogenic in the mouse, but not in any other species (rat, hamster, dog or monkey) (6) (7) (8) (9) . F344 rats chronically treated at dietary concentrations up to 150 mg/kg diet showed no significant increase in hepatocarcinogenicity (10). In contrast, B6C3F1 and CF1 mice were susceptible to hepatocarcinogenicity at © Oxford University Press dieldrin doses as low 2.5 and 1.25 mg/kg respectively (9, 11) . Compounds structurally related to dieldrin, such as chlordane and heptachlor, have also been shown to be selectively hepatocarcinogenic in mice (12, 13) . In contrast, another structurally similar organochloride compound, chlorendic acid, is carcinogenic to both mice and rats (14, 15) . Since a number of hepatocarcinogens are uniquely hepatocarcinogenic in mouse liver, the mechanism for this observed species specificity needs to be further defined (3, 4) .
Many of the organochlorines that produce hepatic cancer appear to be non-genotoxic in nature, functioning at the stage of tumor promotion (2, 16) . Previous studies have shown that endosulfan-a, endosulfan-P, chlordane and heptachlor can facilitate the clonal growth of focal hepatic lesions (2, 16, 17) . While the hepatocarcinogenicity of endosulfan-a and endosulfan-P has not been clearly demonstrated, due to high mortality in chronic feeding studies (17) , chlordane and heptachlor have both been clearly demonstrated to be hepatocarcinogenic (12, 13) . Dieldrin appears to function as a mouse hepatic tumor promoter (4, 5) , while its ability to promote rat hepatic focal lesions remains unclear (18, 19) . Because the B6C3F1 mouse is more susceptible to spontaneously-and chemically-induced hepatocellular cancer when compared with the F344 rat, one reason for the lack of dieldrin hepatocarcinogenicity in rats may be due to an insufficient pool of initiated cells. Alternatively, the lack of carcinogenicity of dieldrin in rats may be due to a biological difference between the two species (4) . In such a case dieldrin may not enhance rat hepatic preneoplastic lesion growth. The present study investigated the ability of dieldrin to enhance preneoplastic lesion growth in mice and rats treated with diethylnitrosamine (DEN*) (20, 21) .
Tumor promotion, the clonal expansion of initiated hepatocytes into preneoplastic lesions, can occur by enhancing the proliferation rate or by decreasing the apoptotic (cell death) rate (22) (23) (24) . Cyproterone acetate, phenobarbital, TCDD and cx-hexachlorocylohexane have been shown to increase focal DNA synthesis, leading to lesion growth (25) (26) (27) . Nafenopin, a peroxisome proliferator, inhibits apoptosis in rat hepatocytes in vitro, resulting in long-term cultures (e.g. months) (28) . In addition, nafenopin, 2,3,7,8-tetrachlorodibenzo-/?-dioxin (TCDD) and phenobarbital have been shown to inhibit apoptosis in rat hepatic focal lesions and enhance apparent lesion growth (29) (30) (31) . These studies suggest that non-genotoxic compounds effect lesion growth via an increase in proliferation and/or a decrease in apoptosis in preneoplastic lesions.
Phenotypic diversity of preneoplastic lesions induced by different non-genotoxic hepatocarcinogens may be responsible for some of the differences in compound hepatocarcinogenicity (22) . Our laboratory and others have shown that phenobarbital selectively enhances eosinophilic preneoplastic lesion growth in mice and rats (32, 33) . However, other non-genotoxic hepatocarcinogens, such as the peroxisome proliferators Wyeth 14,643 K.L.Kolaja et at. Values represent the mean ± SD of the body weight (g) and the relative liver weight (liver to body weight ratio) from five F344 rats per group treated with dieldrin (0.0, 0.1, 1.0, and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. DEN was given to 5-week-old rats twice (one week apart) at a dose of 150 mg/kg body wt. Hepatic focal lesions developed after 4 months. Statistical significance from the DEN-only group (0.0 mg/ kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05). Values represent the mean ± SD of the body weight and the relative liver weight (liver to body weight ratio) from five B6C3F1 mice per group treated with dieldrin (0.0, 0.1, 1.0 and 10.0 mg/kg diet) after formation of preneoplastic lesions with DEN. DEN was given to 5-week-old mice twice a week for 8 weeks at a dose of 25 mg/kg body wt. Hepatic focal lesions developed after 5 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05).
and di(2-ethylhexl)phthalate produce preneoplastic lesions that are basophilic in phenotype (34) . The relevance of distinct morphological preneoplastic lesions selectively produced by certain compounds to the further development of neoplastic lesions remains unclear.
In the present investigation the ability of dieldrin to promote focal lesion growth in mice and rats was investigated. If the selective hepatocarcinogencity of dieldrin in mice (but not rats) is due to a limited pool of initiated cells in rats, then dieldrin should produce promotional effects in both rat and mouse DEN-induced hepatic focal lesions. If, however, the mouse-specific hepatocarcinogenicity of dieldrin is due to intrinsic differences (metabolism of dieldrin, P450 induction after dieldrin treatment, reaction to oxidative stress, etc.) in the mouse, then DEN-induced focal lesions in the rat should not be sensitive to the promotional effects of dieldrin (35) (36) (37) . Dieldrin doses that were previously shown to be either hepatocarcinogenic (10.0 mg dieldrin/kg diet) or non-carcinogenic (0.1 and 1.0 mg dieldrin/kg diet) in chronically fed mice were used to examine the effect of dieldrin upon lesion growth in mice and rats (9) . In addition, the cellular mechanistic roles of alterations in apoptosis and DNA synthesis were examined in distinct morphological preneoplastic lesions. Previous studies by our group and others have indicated that other nongenotoxic hepatocarcinogens can modulate DNA synthesis and apoptosis in preneoplastic lesions to enhance lesion growth (29) (30) (31) 33) , but the effect of dieldrin on focal lesions and the mechanism (apoptosis or cell proliferation) by which dieldrin modifies lesion clonal expansion has not been previously examined.
Materials and methods
Chemicals DEN and bromodeoxyuridine (BrdU) were purchased from Sigma Chemical Co. (St Louis, MO). Dieldrin (98.8% pure) was supplied by Shell Oil Company (Houston, TX). NIH-07 diet containing 0.0 (control), 0.1, 1.0 or 10.0 mg dieldrin/kg diet was formulated by Dyets (Bethlehem, PA). Concentrations of dieldrin were verified by gas chromatography (33) .
Animals
Three-week-old male Fisher 344 rats and male B6C3F1 mice were purchased from Harlan Sprague-Dawley Co. (Indianapolis, IN). Mice and rats were housed in polycarbonate cages with filter tops in an AAALAC certified animal facility. All animals were maintained in accordance with the N1H Guide for the Care and Use of Laboratory Animals. All animals received NIH-07 diet in pelletized form and deionized water ad libitum. All animals were acclimated for 1 week prior to initiation with DEN.
Experimental design
Male Fisher 344 rats were given two i.p. injections (separated by 2 weeks) of 150 mg/kg DEN after the acclimation period to produce hepatic focal lesions and neoplasms (20). After DEN injections three rats were sacrificed for histological examination for the presence of hepatic focal lesions. When focal lesions were histologically apparent (after 4 months) the rats were randomly placed into treatment groups receiving either 0.1, 1.0 or 10.0 mg dieldrin/kg diet or control NIH-07 diet. Adult B6C3FI mice were given two i.p. injections per week of 25 mg/kg DEN for 8 weeks. Similarly to the DENtreated rats, three mice were sacrificed for histological examination for the presence of hepatic focal lesions. When focal lesions were histologically apparent (after 5 months) all mice were randomly placed into one of the above dose groups. Animals were sacrificed 7, 30 or 60 days after dietary treatment. Osmotic minipumps (Alzet Co., Palo Alto, CA) containing 16 mg BrdU/ml phosphate-buffered saline were surgically implanted into five animals from each dose group 7 days prior to each sacrifice time. At sampling animals were humanely killed by carbon dioxide asphyxiation, weighed and necropsied. The livers were removed in tow, weighed and examined for the presence of grossly visible lesions. The livers were then separated by lobe and sectioned Values represent the mean ± SD of the number of focal lesions per liver from five F344 rats per group treated with dieldrin (0.0, 0.1, 1.0 and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Both total foci and foci classified as either basophilic, eosinophilic or clear cell phenotype were examined. DEN was given to 5-week-old rats twice (one week apart) at a dose of 150 mg/kg body wt. Hepatic focal lesions developed after 4 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05). Table IV Values represent the mean ± SD of the hepatic focal lesion volume (%) from five F344 rats per group treated with dieldrin (0.0, 0.1, 1.0 and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Both total foci and foci classified as either basophilic, eosinophilic or clear cell phenotype were examined. DEN was given to 5-week-old rats twice (one week apart) at a dose of 150 mg/kg body wt. Hepatic focal lesions developed after 4 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05). into 1-2 mm strips. Strips of liver from each lobe were fixed in formalin for 48-72 h and then embedded in paraffin. A total of three paraffin blocks per animal were produced. Serial sections (5 u.m thick) for each block were sectioned and stained with hematoxylin and eosin (H&E) or immunohistochemically with anti-BrdU (see below). Preneoplastic lesions were identified as previously described (39) .
Stereology
The volume and number of altered hepatic foci per liver were quantitated using stereological methods (40). Total liver area and hepatocellular lesions were traced, using a projection scope or a drawing tube on a microscope respectively. The liver and focal lesion areas were calculated using Sigma Scan/Image software (Jandel Scientific, Corte Madre, CA) on an IBM computer.
BrdU immunohistochemical staining and quantification
BrdU immunohistochemistry was performed according to previously published methods (41) . The BrdU incorporated into DNA was visualized using the chromagen 3-amino-9-ethyl-carbazole (Zymed, San Francisco, CA) and counterstaining with hematoxylin. Hepatocytes that had incorporated BrdU were visualized by accumulation of red pigment within the nuclei, as compared with the blue nuclei of unlabeled cells. A stretch of duodenum from each animal was included on all liver slides from that animal as a control for proper staining and incorporation of BrdU into the tissue. In focal lesions all hepatocytes were scored for BrdU labeling to ensure an accurate estimation of replicative synthesis. Focal lesion labeling indices were examined by totaling the labeling indices for foci in all mice or rats in that particular treatment group. Labeling index (the percentage of cells in S phase) was determined by dividing the number of hepatocytes with BrdU-labeled nuclei by the total number of hepatocytes counted. Apoptosis H&E stained slides were used to quantitate the incidence of apoptosis. Apoptosis in the liver was defined by previously described morphological characteristics (42, 43) . In addition, the presence of apoptosis was further validated using two unique methodologies; (i) an Apoptag staining kit (Oncor Inc., Gaithersburg, MD); (ii) fluorescent microscopy (31) . The number of apoptotic hepatocytes (at any morphological phase) and the total number of hepatocytes were counted in each focal lesion. The number of apoptotic hepatocytes in a focal lesion was divided by the total number of hepatocytes in that lesion to achieve an apoptotic index. Similarly to labeling index, apoptotic incidence was examined by totaling the incidences from all mice or rats in that particular treatment group.
Statistics
Statistical difference (P < 0.05) from control values for all data was determined by ANOVA followed by Dunnett's post hoc test (44) .
Results
The relative liver weight (the liver weight to body weight ratio) was measured at sampling (Tables I and II) . In rats there were no significant changes in relative liver weight after 7 and 30 days of dietary treatment (Table I ). There was a significant increase, however, in the relative liver weight after 60 days of dietary treatment in the 10.0 mg dieldrin/kg diet treatment group. In mice there was a significant increase in the relative K.L.Kolaja el al. 
Values represent the mean ± SD of the labeling index (%) in hepatic focal lesions from five F344 rats per group treated with dieldrin (0.0, 0.1, 1.0 and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Both total foci and foci classified as either basophilic, eosinophilic or clear cell phenotype were examined. DEN was given to 5-week-old rats twice (one week apart) at a dose of 150 mg/kg body wt. Hepatic focal lesions developed after 4 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05). Values represent the mean ± SD of the incidence of apoptosis (%) in hepatic focal lesions from five F344 rats per group treated with dieldrin (0.0, 0.1, 1.0 and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Both total foci and foci classified as either basophilic, eosinophilic or clear cell phenotype were examined. DEN was given to 5-week-old rats twice (one week apart) at a dose of 150 mg/kg body wt. Hepatic focal lesions developed after 4 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*/> < 0.05).
liver weight after 7 and 30 days of exposure to 10.0 mg dieldrin/kg diet (Table II) . After 60 days of treatment no statistical differences in relative liver weight were observed, partially due to the large variation in the liver weights due to the presence of sizeable tumors. In both mice and rats no significant changes in body weight were observed at any time point (Tables I and II) .
The number of preneoplastic lesions per liver in DENinitiated, dieldrin-treated rats is shown in Table III . In these rats there was no significant increase in the total number of preneoplastic lesions per liver at any time point investigated (Table III) . When the lesions were further characterized by morphological phenotype (eosinophilic, basophilic or clear) no increase in the number of lesions per liver in dieldrintreated rats at any dose or time examined was apparent (Table IE) . Furthermore, dieldrin treatment of DEN-treated rats did not have an effect on either the volume of total focal lesions or on any single phenotypic lesion volume examined (Table IV) . In addition, dieldrin did not increase focal hepatocyte DNA synthesis in the rats (Table V) . No change in the incidence of focal lesion apoptosis was observed at any time examined (Table VI) .
In contrast, there were significant increases in the number of mouse liver focal lesions per liver after 7 days of treatment in both the 0.1 and 10.0 mg dieldrin/kg diet groups (Table VII) . In these dose groups increases in both the number of eosinophilic (0.1 mg dieldrin/kg diet) and the number of basophilic focal lesions (10.0 mg dieldrin/kg diet) were seen. After 30 and 60 days, however, only mice treated with 10.0 mg dieldrin/ kg diet displayed an increased number of preneoplastic lesions per liver, which was reflected in an increased number of both basophilic and eosinophilic liver lesions (Table VII) . Dieldrin treatment of mice also increased the volume of focal lesions after 7 days of treatment with 0.1 and 10.0 mg dieldrin/kg diet (Table VIII) . The increased focal lesion volume was attributed to the increased volume of both eosinophilic and basophilic lesions in the 10 mg dieldrin/kg diet group. In the 0.1 mg dieldrin/kg diet group after 7 days only eosinophilic lesion volume was increased. After 30 days treatment at all three doses of dieldrin (0.1, 1.0 and 10.0 mg/kg diet) increased the lesion volume. The increased lesion volume in these mice was attributed to the increased volume of both basophilic and eosinophilic lesions (Table VIII) . After 60 days of dietary treatment, however, only mice in the 10.0 mg dieldrin/kg diet Values represent the mean ± SD of the number of focal lesions per liver from five B6C3F1 mice per group treated with dieldrin (0, 0.1, 1.0 and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Both total foci and foci classified as either basophilic, eosinophilic or clear cell phenotype were examined. DEN was given to 5-week-old mice twice a week for 8 weeks at a dose of 25 mg/kg body wt. Hepatic focal lesions developed after 5 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05). group still had an increased total lesion volume. At this dose of dieldrin there was an increase in volume of both eosinophilic and basophilic foci. In addition, significant increases in the volume of eosinophilic foci at the 0.1 and 1.0 mg dieldrin/kg diet dose was seen. Table IX shows the labeling index of focal lesions in dieldrin-treated mice. At all time points examined there was an increase in focal labeling index in mice treated with 10.0 mg dieldrin/kg diet. This increased labeling index was observed in both eosinophilic and basophilic lesions. In addition, after 60 days of exposure to 1.0 mg dieldrin/kg diet an increased labeling index of eosinophilic lesions was seen. Table X shows the incidences of apoptosis in focal lesions of different morphological classifications in DEN/dieldrintreated mice. There were no observed differences in the incidence of apoptosis at any dose of dieldrin at any time point examined.
Discussion
In the present study dieldrin selectively enhanced focal lesion growth in mice, but not in rats. Dieldrin treatment of mice led to a selective increase in the number, volume and labeling index of DEN-induced hepatic focal lesions. Increases in these parameters strongly suggests that dieldrin is functioning as a tumor promoter in mice (22) . The lack of observed changes in focal apoptosis suggests that dieldrin enhances the growth of mouse focal lesions via a proliferative mechanism, rather than through reduction of apoptosis (cell death).
Species-specific non-genotoxic hepatocarcinogens (e.g. endosulfan, heptachlor, dieldrin and chlordane) are thought to function at the stage of tumor promotion (2, 16) . Heptachlor and chlordane have been shown to promote hepatocarcinogenesis in DEN-initiated mice, but not in rats (2) . In contrast, endosulfana and endosulfan-P were shown to promote hepatic cancer in DEN-initiated rats (17) . Because the B6C3F1 mouse is associated with a high spontaneous hepatic tumor incidence when compared with the Fisher 344 rat (4), dieldrin may act as a promoter of hepatocarcinogenesis in the mouse due to a substantially larger 'spontaneously' initiated cell population. The results of the present study suggest that dieldrin functions as a tumor promoter in mouse liver, but not rat, despite the presence of focal lesions produced by DEN in the rat.
In contrast, the species-selective effect on the promotion of hepatic focal lesions in mice may be attributed to differences Values represent the mean ± SD of labeling index (%) in hepatic focal lesions from five B6C3F1 mice per group treated with dieldrin (0, 0.1, 1.0 and 10.0 mg/kg diet) for 7, 30 and 60 days after formation of preneoplastic lesions with DEN. Both total foci and foci classified as either basophilic, eosinophilic or clear cell phenotype were examined. DEN was given to 5-week-old mice twice a week for 8 weeks at a dose of 25 mg/kg body wt. Hepatic focal lesions developed after 5 months. Statistical significance from the DEN only group (0.0 mg/kg diet) was determined by ANOVA followed by Dunnett's post hoc test (*P < 0.05). ND (not determined) indicates that an insufficient number of focal lesions were available for evaluation of labeling index. in the induction of hepatic focal lesions. DEN treatment in rats may produce hepatic focal lesions that are bioloigcally different to those produced in the mouse. Likewise, dieldrin may not be able to act as a promoter in our model of DEN initiation due to mutiple mutations occurring in focal leisons producing hepatocytes that are already progressed. However, a recent study in this laboratory has shown that an identical DEN treatment resulted in rat hepatic focal leisons that were susceptible to phenobarbital promotion (33) .
The highest dose of dieldrin examined (10 mg/kg diet) resulted in significant increases in the number, volume and labeling index of mouse preneoplastic lesions. This dose enhanced the growth of both basophilic and eosinophilic foci. The lower doses of dieldrin (0.1 and 1.0 mg/kg diet) did not produce observably consistent promotion effects. A dose of 1.0 mg dieldrin/kg diet only promoted the growth of eosinophilic lesions, as measured by an increased labeling index of eosinophilic focal lesions after 60 days of treatment and an increased eosinophilic lesion volume after 30 and 60 days of treatment. Previous work by Enzmann and Bannasch indicated that basophilic hepatic focal lesions in the rat have a greater propensity than eosinophilic lesions to progress to hepatocellular cancer (45) . However, chronic feeding of dieldrin results primarily in hepatic focal lesions and adenomas that are eosinophilic, suggesting that these lesions are pivotal in dieldrin-induced hepatic cancer (46) . Lastly, the lowest dose (0.1 mg/kg diet) had little effect upon focal lesions, however, a clear no-effect level on tumor promotion was not observed in this study.
In this study the number of hepatic focal lesions per liver was increased in dieldrin-treated mice. This effect of a compound can be attributed to a variety of effects including: (i) acting as a gentoxic agent and producing new initiated cell populations (22) ; (ii) increasing the size of existing lesions such that their detectability in two-dimensional sections of a three-dimensional liver is increased (47); (iii) enhancing growth of focal lesions that were previously histologically non-evident (23) . The lack of genotoxicity of dieldrin in numerous bioassays (1) negates the possibility of dieldrin producing newly initiated cells and suggests that the latter two possibilities are more likely, especially when the effect dieldrin has on hepatic focal DNA synthesis is considered.
Increased DNA synthesis and mitogenesis in normal hepatocytes has been speculated by many to be a cause of hepatocellu-lar cancer induced by non-genotoxic carcinogens (48) (49) (50) (51) (52) (53) (54) (55) (56) . We have previously shown that exposure to 10.0 mg dieldrin/kg diet results in a transient increase in DNA synthesis in mouse, but not rat, liver (48) . In addition, doses of 0.1 and 1.0 mg dieldrin/kg diet did not increase DNA synthesis in either species (48) . This lack of induction of DNA synthesis correlated with previously observed non-carcinogenic doses of dieldrin (9, 48) . It has been suggested that increased DNA synthesis in naive liver may be an indicator of tumor promoting, nongenotoxic hepatocarcinogenic compounds (57) . A dose of 10 mg dieldrin/kg diet in naive hepatocytes resulted in rapid induction, followed by a steadily decreasing rate of DNA synthesis (48) . As shown in the present study, DNA synthesis in hepatic focal lesions in similarly treated mice was persistently elevated throughout the dieldrin treatment.
Enhanced focal growth has been speculated to be an important component in the process of hepatocarcinogenesis (25, 26, 56, 57) . Work by this laboratory and others has indicated that promoter treatment significantly elevates DNA synthesis in hepatic focal lesions when compared with untreated lesions, giving promoter-treated lesions a selective growth advantage (26, 34, 56) . Cyproterone acetate, phenobarbital, TCDD and ahexachlorocylohexane have been shown to increase focal lesion DNA synthesis and lead to enhanced lesion growth (25) (26) (27) . The sustained increase in mouse focal lesion DNA synthesis and lack of an observed decrease in apoptosis in dieldrintreated mice observed in this study suggests that the hepatocarcinogenicity of dieldrin may be mediated via a proliferative mechanism of tumor promotion of focal lesions, rather than an inhibition of focal lesion hepatocyte death (apoptosis). The growth of rodent hepatic focal lesions has predominantly been attributed to an inhibition of programed cell death/apoptosis (28) (29) (30) (31) . The occurrence of this process is rare in normal liver, but the relative rate appears to increase in focal lesions (29) . Recent studies in this laboratory and in others have shown that phenobarbital, nafenopin and TCDD inhibit preneoplastic apoptosis to enhance tumor promotion (28, 29, 31, 33) . In the present study focal hepatocyte apoptosis in mice and rats appeared to be unaffected by dieldrin treatment. This lack of observed effect on apoptosis may be masked by the examination of all focal lesions, whereas apoptosis may be selectively altered in specific focal lesions that may be more likely to progress into neoplasia. However, others have stated that apoptosis may not play a role in the development of hepatocellular cancer (58) . Because apoptosis is a relatively quick process (~3-4 h) which can be influenced by a variety of factors (diet, temperature, steroids, promoters, etc.), a large number of cells can be removed in a relatively short period of time given the proper stimulus (24, 29, 30, 59) . In order to evaluate apoptosis and its role in lesion growth in multistage carcinogenesis properly more information is needed to understand the regulation of this process.
The species difference dieldrin in hepatocarcinogenicity and tumor promotion may be due in part to a difference in the manner in which dieldrin is metabolically handled by the mouse compared with the rat. Studies by Baldwin et al. and Hutson have shown that the rat metabolizes dieldrin more quickly than the mouse, producing mainly pentachloroketone as its metabolite (61,62). While in the mouse dieldrin metabolism results in only very small amounts of pentachloroketone (5% of the urinary metabolites remain unidentified), polar metabolites of dieldrin do not appear in the rat. Thus this difference in metabolism caused by intrinsic differences in the two species may in part account for the species-dependent hepatocarcinogenicity.
The data presented herein indicate that dieldrin acts as a species-specific tumor promoter in DEN-induced hepatic focal lesions in mice. Our data suggest that the lack of carcinogenicity of dieldrin in rats is probably not due to a lack of initiated cells, but rather to a biological difference between the two species. Furthermore, the mechanism by which dieldrininduced mouse preneoplastic lesion growth occurs appears to be attributable more to increased DNA synthesis/cell proliferation than to inhibition of apoptosis.
